Table 1 Analysis across 21 assessed variables
# of patients | % of patients | Hazard ratio for overall survival (range) | P-value | ||
|---|---|---|---|---|---|
Gender | Female | 12 | 39 | 1 | |
Male | 19 | 61 | 1.01 (0.24–4.30) | 0.984 | |
Race, ethnicity | White, non-Hispanic | 14 | 45 | 1 | |
White, Hispanic | 8 | 26 | 1.65 (0.22–11.9) | 0.372 | |
Black, non-Hispanic | 5 | 16 | 2.90 (0.40–20.9) | 0.53 | |
Black, Hispanic | 2 | 6 | 3.08 (0.26–36.4) | 0.29 | |
Not specified | 2 | 6 | |||
ECOG performance status | 0–1 | 20 | 65 | 1 | |
2 | 11 | 35 | 0.60 (0.12–3.01) | 0.54 | |
R-IPI | Very good or good | 13 | 42 | 1 | |
Poor | 18 | 58 | 6.00 (0.74–48.9) | 0.094 | |
Disease stage | 3 | 2 | 6 | 1 | |
4 | 29 | 94 | High | 0.999 | |
Cell of origin | Non-GCB | 10 | 32 | 1 | |
GCB | 10 | 32 | 1.41 (0.31–6.40) | 0.295 | |
Not specified | 11 | 35 | |||
Bulky disease | Yes | 15 | 48 | 1.79 (0.42–7.55) | 0.426 |
Double expressor | Yes | 9 | 29 | 2.02 (0.48–8.49) | 0.338 |
Triple expressor | Yes | 4 | 13 | 0.297 (0.036–2.44) | 0.259 |
CNS involvement prior therapy | Yes | 2 | 6 | 1.26 (0–inf) | 0.999 |
Prior therapy with RCHOP | Yes | 29 | 94 | High | 0.999 |
Prior autologous HSCT | Yes | 12 | 39 | 0.34 (0.06–1.80) | 0.203 |
Age (c) | 29–84 | 31 | 100 | 1.01 (0.956–1.08) | 0.623 |
Ki67% (c) | 40–99 | 29 | 94 | 1.02 (0.96–1.08) | 0.499 |
Not specified | 2 | 6 | |||
LDH at cell infusion (U/L) (c) | 128–1248 | 31 | 100 | 1.00 (1.00–1.00) | 0.003 |
LDH at cell infusion/100 (U/L) (c) | 128–1248/100 | 31 | 100 | 1.34 (1.10–1.64) | 0.003 |
LDH before lymphodepletion (U/L) (c) | 120–1277 | 31 | 100 | 1.41 (1.15–1.72) | 0.0008 |
LDH at disease recurrence (c) | 123–1552 | 31 | 100 | 1.09 (0.92–1.27) | 0.325 |
Number of metastatic sites (c) | 0–6 | 31 | 100 | 1.18 (0.713–1.95) | 0.522 |
CRS (c) | 0–3 | 31 | 100 | 0.94 (0.38–2.32) | 0.891 |
ICANS (c) | 0–4 | 31 | 100 | 1.19 (0.71–2.00) | 0.511 |
CARTOX (c) | 0–10 | 31 | 100 | 0.88 (0.74–1.04) | 0.140 |
Tocilizumab doses (c) | 0–4 | 31 | 100 | 1.04 (0.58–1.88) | 0.886 |